Page 22 - CIBERSAM2016-ENG

Therapeutic Innovation
Coordinator: Francesc Artigas Pérez (Agencia Estatal Consejo Superior de Investigaciones Científicas)
As some of the most relevant results in 2016 achieved by the groups in the programme we could highlight: the publication of one patent (WO2016/020573: Method for monitoring anti-psychotic treatment) and
the publication of around 35 articles in 1st decile journals. Some of these were publications in diverse journals of the Nature group such as Nature Reviews Drug Discovery (FI:47.12), Nature (FI:38.138),
Nature Neuroscience (FI:16.724) and Nature Communications (FI:11.329). Different articles have also been published in other leading journals in the field, such as JAMA Psychiatry (FI:14.417), Molecular Psychiatry (FI:13.314), Cerebral Cortex (FI:8.285) and Neuroscience & Biobehavioral Reviews (FI:8.58). A large percentage of these publications are multi-centre, due to the existence of intra-CIBER cooperation (CIBERSAM and other CIBERs), as well as national and international cooperation. Apart from this, some prior articles of the groups in the programme are considered as being highly cited papers according to the Web of Science.
Apart from this, the groups in the programme continue to be particularly active in recruiting resources, having obtained 21 competitive projects in 2016 from public bodies (MINECO/FEDER: SAF2015-67457-R, SAF2015-68346-P, SAF2015-68436-R, SAF2015-68647-R, SAF 2016/75500-R, SAF2016-75797-R, SAF2016- 76046-R and DPI2016-79075-R; FIS/ISCIII: PI15/00283, PI15/00330, PI15/01246 and CM16/00034; UCM: PR26/16-11B2 and PR26/16-20278) and from different national foundations (FIPSE, Fundación Mapfre and Fundación Alicia Koplowitz) and international bodies (Brain & Behavior Research Foundation).
Some of the awards and distinctions received by members of the team were:
• Prize for Accredited Young Investigator (SEPB) and Early career psychiatrists Scholarship Programme (EPA), going to Dr Iria Grande.
• Appointment of Dr Eduard Vieta as new scientific director of the CIBERSAM.
• Dr Eduard Vieta appears in the list of researchers in the biomedical world most cited in scientific publications (Highly Cited Researchers 2016), drawn up by international agency Thomson Reuters.
Some of the scientific achievements obtained by the different groups in the programme that we could highlight are, amongst others:
• International collaborative study in which genetic variants associated with the response to treatment with lithium in bipolar disorder are found.
• Drawing up and publishing several international clinical guides on treatment for bipolar disorder and an international consensus document for evaluation and handling of agitation in psychiatry.
• Development of novel strategies using RNA interference for studying the physiopathology and treatment of neuropsychiatric affections, including major depressive disorder and Parkinson’s disease.
• The study of the action mechanism of fast-acting anti-depressants, including glutamatergic drugs, such as ketamine.
• Identification of neuronal networks after deep brain stimulation in an animal model of schizophrenia.
• Description of mechanisms for stimulation of innate immunity in schizophrenia in animal and human models and its modulation by antipsychotics.
• Identification of the effects of chronic administration of benzodiazepines and D2 dopamine receptor agonists on the structure of prefrontal cortex neurons.
• Discovery of the implication of the expression of neurligin-2 of prefrontal cortex on the attention deficits induced by peripubertal stress.
• Identification of genetic markers of schizophrenia and of the volume of subcortical structures.
1223